This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Valeant Is Having a Healthy Run

NEW YORK ( TheStreet) -- When an investor comes to me, I can tell where that person is in the Cycle of Disappointment.

First is the investor fresh from one of the big wire houses whose portfolios are full of well-known stocks that ran out of gas years ago.I'm thinking of stocks like Cisco (CSCO) and Pfizer (PFE) and Lilly (LLY).

Maybe there are a lot of bonds in there, too. That potential client did everything right, but still the returns were all wrong. The S&P 500 was up nearly 30% over the past year. Old stocks and old theories don't work, and some of these investors are just barely ahead for 2013.

Second is the do-it-yourselfer. After seeing the guys in suits underperform the market, this investor figures "how hard could it be?" and starts laying his own money down.

There is a lot of trading for a lot of the wrong reasons. I see lots of imbalances, maybe too much money in one stock, and people who underestimate the time and energy it takes to keep an eye on the market.

When I talk with them we discuss how markets have sectors, and how we should look for good stocks inside of hot sectors. This year, pharmaceuticals and biotechs have been hot.

As I checked out a potential client's portfolio the other day, I saw a few pharmaceutical companies including Pfizer, Lilly and Merck (MRK). But are these the pharmas to hold in the future? Not really.

Last year was good to the pharmaceuticals. In fact, pharma is now my third-ranked sector in the market.

Data from Best Stocks Now App

One stock that gets high marks from my Best Stocks Now app is Valeant Pharmaceuticals (VRX - Get Report).

Data from Best Stocks Now App

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
VRX $210.42 0.00%
TSLA $218.42 0.00%
YHOO $44.52 0.00%
AAPL $130.28 0.00%
FB $81.53 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs